Select Bibliography

Filter by any of these (after searching):

Owzar, Kouros

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 7 items

Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).

Hatch, Ace Joseph , Pang, Herbert , Starr, Mark D. , Brady, John C. ... - ASCO - J Clin Oncol - 2014

Abstract - Secondary-not-in-original - Primary - GI - CALGB-80203

A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance).

Hertz, Daniel Louis , Jiang, Chen , Owzar, Kouros , Halabi, Susan ... - ASCO - J Clin Oncol - 2014

Abstract - Primary - Primary - PPP - CALGB-60404 , CALGB-90401

Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J Clin Oncol - 2015

Abstract - Primary - Long-Term-Followup - Myeloma - CALGB-100104

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J Clin Oncol - 2015

Abstract - Secondary - Primary - PPP - CALGB-80405

A Genome-Wide Association Study (GWAS) Of Survival In Metastatic Breast Cancer (MBC) Patients Treated With Letrozole (L) With Or Without Bevacizumab (B) In CALGB 40503 (Alliance)

Innocenti, Federico , Owzar, Kouros , Jiang, Chen ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary-not-in-original - Primary - PPP - CALGB-40503

Blood-based biomarkers (BMs) in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI + bevacizumab (Bev), cetuximab (Cetux) or Bev + Cetux: Results from CALGB 80405

Nixon, Andrew B. , Sibley, Alexander B. , Hatch, Ace J. ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary - Primary - Correl Sci NOS - CALGB-80405

Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance).

Patel, Jai Narendra , Jiang, Chen , Hertz, Daniel Louis ... - ASCO - J Clin Oncol - 2014

Abstract - Secondary-not-in-original - Primary - GU - CALGB-90401